Cancer Research

Gateway Traditional Grant Program 
Core grants funding early phase clinical trials for cancers of all types at renowned institutions around the world. These grants are typically 2-5 years in duration with award amounts from $200,000 to $1.5 million. 
NCI/ SPORE/ P20 Program 
Collaboration with National Cancer Institute (NCI)/Specialized Programs of Research Excellence (SPORE)/ P20 Program focuses on more patient-centric research. This grant program will support translational research through clinical trials conducted by institutions that receive NCI SPORE awards. Gateway will issue grant awards based on an application and review process conducted by Gateway.
Integrative Research  
Gateway focuses on funding integrative oncology research that pairs conventional therapies with evidence-based, complementary therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life during treatment.  
Society for Integrative Oncology (SIO) 
Our collaboration with the Society for Integrative Oncology (SIO) allows us to bring the most promising patient-centered, integrative oncology research proposals forward, Gateway collaborates with SIO to support integrative clinical trials conducted by principal investigators and institutions among its membership. SIO’s mission is to advance evidence-based, comprehensive, integrative healthcare to improve the lives of people affected by cancer.
Decentralized Clinical Trial Initiative (DCTI) 
During the COVID-19 pandemic, we launched a new grant program to fund research leveraging site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients’ doorsteps.